

alteplase (ACTivase) 50 mg injection

SUPPLIES *include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed*

*****NS flush syringes are never to be used for reconstitution/diluent for medication.*****

- One (1) alteplase kit, which contains one (1) 50 mg alteplase powder vial packaged with one (1) diluent for reconstitution - 50 mL sterile water for injection (SWFI) vial
- Alcohol swabs
- Two-three (2-3) 18 gauge needles preferred (20-23 gauge needles acceptable)
- One-two (1-2) 50 mL sterile syringe(s)
- One (1) appropriate syringe size for patient specific dose
- Nursing IV admixture label(s) – Lawson # 626

STEPS *explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)*

1. Wash hands. Prepare/clean the designated mixing area.
2. Flip the cap off of the 50 mg alteplase vial and 50 mL SWFI vial and wipe the rubber stoppers with alcohol swabs.
3. Attach 18 gauge needle to syringe. Withdraw 50 mL of SWFI and add to alteplase vial to reconstitute, directing the SWFI stream into the lyophilized cake. There should be vacuum drawing SWFI into the alteplase vial. **DO NOT USE IF VACUUM IS NOT PRESENT.**
4. Gently invert vial to mix. Do not shake. Slight foaming is not unusual; let stand undisturbed for several minutes to allow large bubbles to dissipate.
5. Visually inspect solution (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects.
6. Label the vial containing reconstituted solution with:
 - a. Drug name, strength, and dose (if not apparent by the container)
 - b. Diluent and volume (if not apparent by the container)
 - c. Hang-by date and time (**administration must begin within 1 hour from the time of compounding**)
 - d. Initials of person compounding
7. If syringe for IV push is needed:
 - a. Attach 18 gauge needle to appropriate size syringe and withdraw patient-specific dose per order from the reconstituted alteplase vial.
 - b. Visually inspect the final syringe for particulate matter/defects. Discard if any defects. Discard the alteplase vial once dose is withdrawn.
 - c. Label the final syringe with the following information:
 - i. Patient name and location
 - ii. Drug name, strength, and dose (if not apparent by the container)
 - iii. Diluent and volume (if not apparent by the container)
 - iv. Hang-by date and time (**administration must begin within 1 hour from the time of compounding**)
 - v. Initials of person compounding

NOTES *explicitly state any pertinent information*

- 50 mg powder vial contains vacuum. **DO NOT USE IF VACUUM IS NOT PRESENT.**

References

- alteplase (Activase) for injection [prescribing information]. South San Francisco, CA: Genentech, Inc. Revised 9/2022.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2&type=display>.
- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia.
<https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness>